Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia
Brief Summary: To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4 weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen. The dose regimen of 75 mg every 2 weeks (Q2W), as used in other studies, was added as a calibrator.


Options:
A: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Alirocumab, Drug: Placebo (for Alirocumab), Drug: Non-statin LMT, Other: Diet Alone | Arm Label: Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator); Type: OTHER; Interventions: Drug: Alirocumab, Drug: Non-statin LMT, Other: Diet Alone | Arm Label: Alirocumab 150 mg Q4W/Up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for Alirocumab), Drug: Non-statin LMT, Other: Diet Alone | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 150 mg Q4W/Up to 150 mg Q2W, Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator), Placebo Q2W | Intervention Type: DRUG; Name: Placebo (for Alirocumab); Assigned to Arm(s): Alirocumab 150 mg Q4W/Up to 150 mg Q2W, Placebo Q2W | Intervention Type: DRUG; Name: Non-statin LMT; Assigned to Arm(s): Alirocumab 150 mg Q4W/Up to 150 mg Q2W, Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator), Placebo Q2W | Intervention Type: OTHER; Name: Diet Alone; Assigned to Arm(s): Alirocumab 150 mg Q4W/Up to 150 mg Q2W, Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator), Placebo Q2W
B: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Intervention Type: DRUG; Name: REGN727; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4
C: Arm Label: Atorvastatin (statin rechallenge arm); Type: OTHER; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Drug: Placebo | Arm Label: Alirocumab 75 mg/ up to 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin (statin rechallenge arm) | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg, Atorvastatin (statin rechallenge arm), Ezetimibe
D: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Statin | Arm Label: Alirocumab 75 mg/ Up 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Placebo (for alirocumab), Drug: Alirocumab, Drug: Statin | Arm Label: Alirocumab 300 mg/ Up 150 mg Q4W; Type: EXPERIMENTAL; Interventions: Drug: Placebo (for alirocumab), Drug: Alirocumab, Drug: Statin | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Alirocumab 300 mg/ Up 150 mg Q4W, Alirocumab 75 mg/ Up 150 mg Q2W, Placebo Q2W | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 300 mg/ Up 150 mg Q4W, Alirocumab 75 mg/ Up 150 mg Q2W | Intervention Type: DRUG; Name: Statin; Assigned to Arm(s): Alirocumab 300 mg/ Up 150 mg Q4W, Alirocumab 75 mg/ Up 150 mg Q2W, Placebo Q2W

Answer: D